JP2017526728A - 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト - Google Patents

炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト Download PDF

Info

Publication number
JP2017526728A
JP2017526728A JP2017514446A JP2017514446A JP2017526728A JP 2017526728 A JP2017526728 A JP 2017526728A JP 2017514446 A JP2017514446 A JP 2017514446A JP 2017514446 A JP2017514446 A JP 2017514446A JP 2017526728 A JP2017526728 A JP 2017526728A
Authority
JP
Japan
Prior art keywords
montelukast
levocetirizine
virus
combination
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017514446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526728A5 (https=
Inventor
ブルース・チャンドラー・メイ
Original Assignee
インフラマトリー・レスポンス・リサーチ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インフラマトリー・レスポンス・リサーチ・インコーポレイテッド filed Critical インフラマトリー・レスポンス・リサーチ・インコーポレイテッド
Publication of JP2017526728A publication Critical patent/JP2017526728A/ja
Publication of JP2017526728A5 publication Critical patent/JP2017526728A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017514446A 2014-09-15 2015-09-11 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト Pending JP2017526728A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462050668P 2014-09-15 2014-09-15
US62/050,668 2014-09-15
PCT/US2015/049767 WO2016044095A1 (en) 2014-09-15 2015-09-11 Levocetirizine and montelukast in the treatment of inflammation mediated conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020070422A Division JP2020109128A (ja) 2014-09-15 2020-04-09 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト

Publications (2)

Publication Number Publication Date
JP2017526728A true JP2017526728A (ja) 2017-09-14
JP2017526728A5 JP2017526728A5 (https=) 2018-10-11

Family

ID=55533713

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017514446A Pending JP2017526728A (ja) 2014-09-15 2015-09-11 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト
JP2020070422A Pending JP2020109128A (ja) 2014-09-15 2020-04-09 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020070422A Pending JP2020109128A (ja) 2014-09-15 2020-04-09 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト

Country Status (4)

Country Link
US (4) US9925183B2 (https=)
EP (1) EP3193875B1 (https=)
JP (2) JP2017526728A (https=)
WO (1) WO2016044095A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209035A1 (ko) * 2018-04-27 2019-10-31 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR20190125943A (ko) * 2018-04-27 2019-11-07 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
JP2022500437A (ja) * 2018-09-14 2022-01-04 ジャンイン ユスン ファーマシューティカル カンパニー，リミテッド モンテルカストおよびペプチドの新規接合体
JP2023517537A (ja) * 2020-03-02 2023-04-26 ファルマ、マール、ソシエダード、アノニマ 自己免疫状態に使用するための化合物
JP2023517536A (ja) * 2020-03-02 2023-04-26 ファルマ、マール、ソシエダード、アノニマ 炎症状態に使用するための化合物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130050952A (ko) 2010-06-16 2013-05-16 브루스 챈들러 메이 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
RU2015134423A (ru) 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
WO2014164285A2 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
MX382776B (es) 2013-03-13 2025-03-13 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
AU2019334202A1 (en) 2018-09-06 2021-03-25 Innopharmascreen, Inc. Methods and compositions for treatment of asthma or parkinson's disease
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2021236518A1 (en) * 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
KR102935859B1 (ko) 2022-08-12 2026-03-06 아주대학교산학협력단 펙소페나딘을 포함하는 퇴행성 신경질환의 예방, 개선 또는 치료용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180868A1 (en) * 2003-03-12 2004-09-16 Mullally John P. Composition and method for treating inflammations by reducing C-reactive protein
US20050256131A1 (en) * 2002-05-24 2005-11-17 Carl-Fr Coester Pharmaceutical active substance combination and the use thereof
JP2013528654A (ja) * 2010-06-16 2013-07-11 ブルース・チャンドラー・メイ インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用
WO2013148366A1 (en) * 2012-03-27 2013-10-03 Duke Unversity Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
CN103505731A (zh) * 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
WO2014090990A1 (en) * 2012-12-13 2014-06-19 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801612A (en) 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
US5211958A (en) 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US5147637A (en) 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
JPH07503629A (ja) 1991-11-14 1995-04-20 アライアンス　ファーマシューティカル　コーポレイション フルオロカーボンを用いた部分的液体呼吸法および装置
WO1995009652A1 (en) 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Treatment of autoimmune and inflammatory disorders
KR20000070460A (ko) 1997-01-24 2000-11-25 왈리스 조 앤 메토트렉세이트와 공동으로 내성화를 사용한 자기면역질병의 치료
PL193131B1 (pl) 1997-12-23 2007-01-31 Schering Corp Kompozycja farmaceutyczna zawierająca kombinację składników aktywnych i jej zastosowanie
WO1999037155A1 (en) 1998-01-27 1999-07-29 Nutramax Laboratories, Inc. Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US7186555B1 (en) 1999-04-13 2007-03-06 The Feinstein Institute For Medical Research Prevention of brain damage in stroke
US20020006961A1 (en) 1999-05-14 2002-01-17 Katz Stanley E. Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US20010051624A1 (en) 2000-04-12 2001-12-13 Jones Thomas R. Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
WO2002009699A2 (en) 2000-07-28 2002-02-07 Immupharm Aps Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
US7718198B2 (en) 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
CA2451519C (en) 2001-06-28 2007-11-06 Ucb, Farchim, S.A. Tablet comprising cetirizine and pseudoephedrine
EP1471907B1 (en) 2001-06-29 2008-07-16 AB Science Use of c-kit inhibitors for treating autoimmune diseases
HU224941B1 (en) 2001-08-10 2006-04-28 Bgi Innovacios Kft Phototerapy apparatus
WO2003101434A2 (en) 2001-12-21 2003-12-11 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
US20060263350A1 (en) 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2006010283A1 (en) 2004-07-28 2006-02-02 Universität Zürich Prevention and treatment of thrombus formation
CA2580271A1 (en) 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
US20070225285A1 (en) * 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070244128A1 (en) 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
WO2007056510A2 (en) 2005-11-09 2007-05-18 The Children's Hospital Of Philadelphia Chloride transport upregulation for the treatment of traumatic brain injury
NZ591969A (en) 2005-12-21 2012-05-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-adrenoceptor agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
US7589076B2 (en) 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
EP2559434A3 (en) 2007-02-12 2013-05-29 Mike Nicolaou Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
EP2175856A4 (en) 2007-08-15 2011-08-24 Chemagis Ltd NOVEL PROCESS FOR THE PREPARATION OF HIGH-PURITY LEVOCETRIXIN AND ITS SALTS
EP2209769A1 (en) 2007-10-25 2010-07-28 Merck Frosst Canada Ltd. Novel crystalline salts of montelukast
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
EP2215260A4 (en) 2007-10-25 2011-04-20 Revalesio Corp COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION
CN102414196A (zh) 2009-03-02 2012-04-11 基因里克斯(英国)有限公司 改进的方法
WO2010107404A1 (en) 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
BR112012018913A2 (pt) 2010-01-28 2017-06-20 Merck Sharp & Dohme "composição farmacêutica, e, uso da composição"
US20120002637A1 (en) 2010-06-18 2012-01-05 Interdigital Patent Holdings, Inc. Method and apparatus for supporting home node-b mobility
JP2013535456A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
TR201009398A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
JP5996553B2 (ja) 2010-12-30 2016-09-21 ジブ エム．ディー． ハリシュ， 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物
US20130030009A1 (en) 2010-12-30 2013-01-31 Ziv Harish Method for the treatment and/or prevention of oral allergic symptions of the lips due to oral contact with a food allergen
US20120263764A1 (en) * 2011-04-13 2012-10-18 Revalesio Corporation Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
EP2520292A1 (en) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
KR20130009553A (ko) 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
CN103827090B (zh) 2011-07-26 2016-04-20 勃林格殷格翰国际有限公司 取代的喹啉及其作为药物的用途
CN102895661A (zh) 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
MX382776B (es) 2013-03-13 2025-03-13 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
RU2015134423A (ru) 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
WO2014164285A2 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
RU2705097C2 (ru) 2013-03-13 2019-11-05 Ирр, Инк. Применение левоцетиризина и монтелукаста при лечении анафилаксии
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
WO2017210417A1 (en) 2016-06-03 2017-12-07 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of radiation-mediated conditions
WO2021236518A1 (en) 2020-05-19 2021-11-25 IRR, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256131A1 (en) * 2002-05-24 2005-11-17 Carl-Fr Coester Pharmaceutical active substance combination and the use thereof
US20040180868A1 (en) * 2003-03-12 2004-09-16 Mullally John P. Composition and method for treating inflammations by reducing C-reactive protein
JP2013528654A (ja) * 2010-06-16 2013-07-11 ブルース・チャンドラー・メイ インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用
WO2013148366A1 (en) * 2012-03-27 2013-10-03 Duke Unversity Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
CN103505731A (zh) * 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
WO2014090990A1 (en) * 2012-12-13 2014-06-19 Ludwig Aigner Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEUROPHARMCOLOGY, vol. 79, JPN6019019029, April 2014 (2014-04-01), pages 707 - 714, ISSN: 0004041719 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209035A1 (ko) * 2018-04-27 2019-10-31 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR20190125943A (ko) * 2018-04-27 2019-11-07 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR20200116069A (ko) * 2018-04-27 2020-10-08 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR20200116068A (ko) * 2018-04-27 2020-10-08 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR102269665B1 (ko) 2018-04-27 2021-06-28 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR102269664B1 (ko) 2018-04-27 2021-06-28 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
KR102269663B1 (ko) 2018-04-27 2021-06-28 주식회사 레모넥스 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물
JP2022500437A (ja) * 2018-09-14 2022-01-04 ジャンイン ユスン ファーマシューティカル カンパニー，リミテッド モンテルカストおよびペプチドの新規接合体
JP7759693B2 (ja) 2018-09-14 2025-10-24 ジャンイン ユスン ファーマシューティカル カンパニー，リミテッド モンテルカストおよびペプチドの新規接合体
KR102946621B1 (ko) * 2018-09-14 2026-04-01 장인 우선 파마슈티컬 컴퍼니 리미티드 몬테루카스트와 펩티드의 새로운 접합체
JP2023517537A (ja) * 2020-03-02 2023-04-26 ファルマ、マール、ソシエダード、アノニマ 自己免疫状態に使用するための化合物
JP2023517536A (ja) * 2020-03-02 2023-04-26 ファルマ、マール、ソシエダード、アノニマ 炎症状態に使用するための化合物

Also Published As

Publication number Publication date
EP3193875A4 (en) 2018-05-23
US9925183B2 (en) 2018-03-27
JP2020109128A (ja) 2020-07-16
US20180169091A1 (en) 2018-06-21
EP3193875A1 (en) 2017-07-26
WO2016044095A1 (en) 2016-03-24
EP3193875B1 (en) 2022-02-16
US10195193B2 (en) 2019-02-05
US20190201393A1 (en) 2019-07-04
US20170173001A1 (en) 2017-06-22
US20210177835A1 (en) 2021-06-17
US11590125B2 (en) 2023-02-28
US10792281B2 (en) 2020-10-06

Similar Documents

Publication Publication Date Title
US11590125B2 (en) Levocetirizine and montelukast in the treatment of inflammation mediated conditions
AU2025210905A1 (en) Method of treatment with tradipitant
BR112021002945A2 (pt) dosagem noturna crônica de lasmiditan para prevenção de enxaqueca
Karthika et al. COVID-19, the firestone in 21st century: a review on coronavirus disease and its clinical perspectives
EP4370131A1 (en) Methods of treating alzheimer's disease
Vrinten et al. Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes
Saha et al. Individualized homoeopathy versus placebo in essential hypertension: A double-blind randomized controlled trial
US20250090522A1 (en) Levocetirizine and montelukast in the treatment of coronavirus disease and symptoms thereof
US20180318338A1 (en) Methods and compositions for the prevention of suicide, homicide and self-harming behaviors
HK1240843B (en) Levocetirizine and montelukast in the treatment of inflammation mediated conditions
HK1240843A1 (en) Levocetirizine and montelukast in the treatment of inflammation mediated conditions
Mythri et al. Coronavirus disease-19 vaccination and chemosensory dysfunction
Anderer NIH: Adults Still Using Marijuana and Psychedelics at Record Levels
Anderer High drug costs influence nonadherence to medications among older adults
Peterson An experimental evaluation of central pain processing following COVID-19 infection
Aliev et al. Infectious Burden and Alzheimer Disease: Is There a Link?
Lucius Long COVID: From Mechanisms to Natural Therapies
Cabaret False resistance to antiparasitic drugs: causes from shelf availability to patient compliance
WO2024180199A1 (en) Compositions and methods for treating charcot–marie–tooth disease
Shah et al. A Randomized, Placebo-controlled Homeopathic Drug-proving of SARS CoV-2 nosode (BiosimCovex) in healthy volunteers: Homeopathic Pathogenetic Trial of SARS CoV-2 nosode
Anderer Caseload Strain Contributed to 1 in 5 COVID-19 Deaths at US Hospitals
Anderer Study: Starting Second-Trimester Abortions at Home Safely Reduces Hospital Time
Anderer New Tick-Borne Virus Identified in China
Anderer CDC Reports Human Case of Bird Flu Not Linked to Animals
Anderer Study: Fentanyl’s Arrival, Not Oregon’s Drug Law, Likely Explains State’s Overdose Surge

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191209